The GLP-1 that
outperforms everything
before it.
Retatrutide is a first-in-class triple agonist acting on GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 results showed a 24.2% mean body weight reduction — exceeding every approved incretin therapy on record.
Listed on Ascension Peptides as R-10 (10mg) and R-30 (30mg). Visitors from this page receive 50% off automatically — search either name to find the product.
// Source: Jastreboff et al., NEJM 2023
// Source: Jastreboff et al., NEJM 2023
Triple Receptor Activity.
One Peptide.
GLP-1 Receptor
Slows gastric emptying, increases satiety signaling and amplifies glucose-dependent insulin release — the proven foundation of every modern incretin therapy.
GIP Receptor
Adds glucose-dependent insulin secretion plus improved lipid handling, amplifying the GLP-1 effect and improving tolerance at higher therapeutic doses.
Glucagon Receptor
Drives hepatic energy expenditure and lipolysis. Retatrutide is the first triple agonist to safely engage this third arm in human trials.
Ascension Peptides lists Retatrutide under a different name.
Because Retatrutide is still an investigational compound, Ascension Peptides lists it using their internal naming system. You won't find it by searching "Retatrutide" on their site — search for R-10 or R-30 instead.
R-10
10mg vial. Entry-level research quantity. Ideal for initial protocols and dose titration work.
R-30
30mg vial. Larger research quantity. Better value per mg for extended study protocols.
Can't find it? Search "R-10" or "R-30" directly on their site.
Quality Assured
Our products are third-party tested to guarantee potency and are contaminant-free.
Let's talk about
Peptide Purity.
>99% — Suitable for quantitative assays & structural studies
Purity isn't a marketing line — it determines whether your data is interpretable. Sub-95% preparations introduce confounding peptide fragments, residual solvents and salt artifacts that contaminate every downstream measurement.
- NMR spectroscopy studies
- Receptor-ligand interaction studies
- Peptides used as final quantitative references
- Blocking and competition assays
- Enzyme-substrate studies
How Retatrutide
actually burns fat.
Retatrutide targets three hormone receptors simultaneously — a triple-agonist mechanism unlike older treatments which focus on a single pathway. That's why the data looks fundamentally different.
Users describe a total lack of "food noise" that feels different from other medications. The GLP-1 component slows gastric emptying and reduces hunger signaling at the source.
The glucagon receptor increases energy expenditure and fat oxidation, meaning your body burns more calories even at rest — not just less intake, but more output.
No weight loss plateau was observed in trials. Participants continued their downward trajectory through the full study period — unlike older GLP-1 drugs that typically stall.
The visceral fat data is
what sets it apart.
Visceral fat — the dangerous fat surrounding your organs — is directly linked to heart disease, type 2 diabetes, and chronic inflammation. Losing weight on the scale doesn't always mean losing visceral fat. With retatrutide, it does.
Visceral fat (around internal organs) dropped at 48 weeks
Subcutaneous fat under the skin decreased significantly
Liver fat reduction at higher doses in the Phase 2 trial
Of participants on the highest dose reached normal liver fat (<5%)
Liver Fat
These findings put retatrutide near the top of the class across all molecules currently being investigated for liver fat reduction.
Metabolic Markers
Insulin resistance decreased significantly — fasting insulin levels dropped by up to 71% at higher doses, and triglycerides fell by over 40%.
Retatrutide titration schedule.
Unlike some compounds where you start at the treatment dose, retatrutide uses a gradual dose escalation (titration) protocol — beginning at a low dose and increasing in defined steps over several weeks. This is because it activates three different receptors (GLP-1, GIP, and glucagon), each affecting gut motility, appetite, blood sugar, and energy expenditure. It’s administered as a once-weekly subcutaneous injection.
| Phase | Weeks | Weekly Dose | What Happens |
|---|---|---|---|
| Starting | Weeks 1–4 | 2 mg | Starting dose. Most users acclimate over the first 1–2 weeks; nausea peaks early then attenuates. |
| Step 1 | Weeks 5–8 | 4 mg | First titration step. Appetite suppression becomes noticeable. |
| Step 2 | Weeks 9–12 | 6 mg | Intermediate step used in Phase 3 TRIUMPH trials (Phase 2 skipped 6 mg). |
| Step 3 | Weeks 13–16 | 8 mg | Often called the “sweet spot” — produces nearly the same results as 12 mg with fewer side effects. |
| Maintenance | Weeks 17+ | 12 mg | Highest investigational dose, associated with the strongest weight loss results. |
Two main published schedules. Phase 2 (NEJM 2023) used 2→4→8→12 mg with no 6 mg step. Phase 3 TRIUMPH added an intermediate 6 mg step.
Start low, go slow
Jumping to high doses overwhelms the three receptor systems. Participants who started at 4 mg instead of 2 mg had significantly higher rates of GI side effects.
Step up every 4 weeks
The titration steps up every 4 weeks so the body can adjust before higher doses are reached.
The 8 mg sweet spot
8 mg produces nearly the same results as 12 mg with fewer side effects, making it a potential sweet spot for many.
In clinical trial protocols, if a weekly dose was missed and 5 or fewer days had passed, the dose could be taken when remembered.
Product tie-in
R-10 (10mg) is ideal for early titration phases and dose-finding work. R-30 (30mg) suits extended protocols once at maintenance dosing.
Shop R-10 & R-30 — 50% offThis information is for educational and research discussion purposes only and does not provide medical or clinical dosing instructions. Two things are intentionally absent and need a clinician’s judgement, not a dosage chart: whether retatrutide is appropriate at all, and individual indications, comorbidities, and baseline labs.
What researchers and
users are saying.
"The food noise just disappeared. Before I could eat a whole steak and sides and still feel hungry — now I can't even finish a regular burger."
"Reddit communities have nicknamed it the "Godzilla" of weight loss — users describe a total absence of food noise that feels different from anything else they've tried."
"Some users transitioning from tirzepatide to retatrutide reported not just continued weight loss, but improved mental clarity and focus."
"In the trial, most participants lost nearly a quarter of their body weight — with a subset losing over 30% after 48 weeks on the highest dose. For some, weight loss hadn't even plateaued."
Community and forum reports are anecdotal and shared for informational research context only. Individual results vary. Nothing on this page constitutes medical advice.
How retatrutide stacks against
predecessors.
In the Phase 3 TRIUMPH-4 trial, participants taking retatrutide 12mg lost an average of 28.7% of their body weight (71.2 lbs) at 68 weeks — even higher than the Phase 2 figures shown below.
| Compound | Receptor Targets | Duration | Weight Loss Peak | Phase |
|---|---|---|---|---|
RetatrutideHighest on record | GLP-1 · GIP · Glucagon | Weekly | 24.2% | Phase 2 |
Tirzepatide | GLP-1 · GIP | Weekly | 22.5% | Approved |
Semaglutide | GLP-1 | Weekly | 15.3% | Approved |
Liraglutide | GLP-1 | Daily | 8.4% | Approved |
Ozempic | GLP-1 | Weekly | 6.1% | Approved |
Common questions about
Retatrutide.
What is Retatrutide?
Retatrutide is a first-in-class triple agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously — the only investigational compound currently engaging all three pathways at once.
How is it different from Ozempic or Mounjaro?
Ozempic (semaglutide) targets one receptor (GLP-1). Mounjaro (tirzepatide) targets two (GLP-1 and GIP). Retatrutide targets all three — including glucagon, which drives the metabolic-boost effect — producing larger documented fat loss in trials.
How often is it used?
Retatrutide has roughly a six-day half-life, designed for once-weekly subcutaneous administration in clinical research protocols.
Does it help with belly / visceral fat?
Yes — this is one of its standout features. Trials showed up to 48% reduction in visceral fat (the dangerous fat surrounding internal organs) at 48 weeks, alongside major reductions in liver fat.
What are the common side effects?
The most common adverse events reported in trials were nausea, vomiting, and diarrhea — generally mild-to-moderate and most commonly seen during dose escalation periods.
Where do I find it?
Ascension Peptides lists it under their internal naming system as R-10 (10mg) and R-30 (30mg). Visitors from this page receive 50% off automatically at checkout.
What researchers report
over time.
Titration & Adaptation
Low dose initiation to establish tolerance. Appetite signaling begins to shift; minimal weight movement expected.
Primary Reduction Window
Steepest weight reduction curve. Receptor occupancy stabilizes; metabolic rate measurably increases.
Sustained Reduction
Continued steady reduction with body recomposition effects. Glucose & lipid markers normalize.
End-Point & Discontinuation
Peak reduction documented in trial. Protocol off-ramp begins; long-term maintenance data under review.
Get 50% off Retatrutide at Ascension Peptides.
This discount is only available to visitors coming through this page. Listed as R-10 (10mg) and R-30 (30mg). Third-party tested, COA-verified supply.
Claim 50% Off — Shop R-10 & R-30Discount applied automatically. Can't find it? Search "R-10" or "R-30" on their site.
RESEARCH USE ONLY. Retatrutide is an investigational compound. Not approved by the FDA for human use, treatment, diagnosis, or prevention of disease. Content on this site is provided for informational and educational purposes only and does not constitute medical advice. Products discussed are intended for in-vitro laboratory research by qualified investigators in a controlled setting. This site contains affiliate links — outbound purchases through the Ascension Peptides link may generate a referral commission at no additional cost to the buyer.